Drug Database
Back to search

Belgium· BE-AMP-SAM564666-00

Zeposia 0.23 mg - 0.46 mg

A ozanimod product containing ozanimod hydrochloride, registered in Belgium by Bristol-Myers Squibb Pharma. The same ATC class is registered in 13 of our 19 countries.

ATC L04AE02

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedZeposia 0.23 mg - 0.46 mgATCL04AE02REGISTER NO.BE-AMP-SAM564666-00PACKS LISTED2CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about ozanimod hydrochlorideAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Ozanimod is registered in 13 of 19 countries.

Countries holding a registration under ATC L04AE02 (ozanimod), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 8 of them publish a price we can compare per daily dose
Search ozanimod products by name

Ozanimod · ATC L04AE02

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of ozanimod costs, country by country.

Normalised to the WHO defined daily dose (0.92 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Ozanimod · price per daily dose (0.92 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$85.78
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Ozanimod Hydrochloride
Manufacturer
Bristol-Myers Squibb Pharma
Country
Belgium (BE)
ATC code
L04AE02
ATC class
Ozanimod
Defined daily dose
0.92 mg, O
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 2

1 priced
  • be_apb
    7733181
  • be_apb
    4225728
    EUR 322.96

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

852 interactions on record for ozanimod.

Graded by severity as the source publishes them — 578 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check ozanimod against other medicinesHow interaction checks work

Ozanimod · interactions on record

852 records

  • 578 severe
  • 271 moderate
  • 3 minor

Most severe, free to view

  • FamotidineA02BA03severe
  • PapaverineA03AD01severe
  • IsomethepteneA03AX10severe
  • CisaprideA03FA02severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Ozanimod in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ozanimod products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Zeposia
  • Liechtenstein · Zeposia
  • Norway · Zeposia

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/abc64639-467e-4e9d-abb9-2d58e91d7bbc
GET /v1/drugs/abc64639-467e-4e9d-abb9-2d58e91d7bbc?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Capsule, hard",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Zeposia 0.23 mg - 0.46 mg",
  "name_fr": "Zeposia 0.23 mg - 0.46 mg",
  "name_nl": "Zeposia 0.23 mg - 0.46 mg",
  "amp_code": "SAM564666-00",
  "strengths": [
    "0.4600",
    "0.2300"
  ],
  "pack_count": 1,
  "substances": [
    "Ozanimod Hydrochloride",
    "Ozanimod",
    "Potassium Hydroxide",
    "Propylene Glycol"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Ozanimod",
  "authorisation_numbers": [
    "EU/1/20/1442/001"
  ]
}
API referenceMCP serverPlans

See everything about ozanimod.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console